5-(methylsulfonamido)-2-nitrobenzamide | 1256489-05-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(methylsulfonamido)-2-nitrobenzamide
• 英文别名: 5-(Methanesulfonamido)-2-nitrobenzamide；5-(methanesulfonamido)-2-nitrobenzamide
• CAS: 1256489-05-0
• 化学式: C₈H₉N₃O₅S
• 分子量: 259.243
• InChiKey: OWBJBVSPDZYRDG-UHFFFAOYSA-N

物化性质

• 沸点：
  435.3±55.0 °C(Predicted)
• 密度：
  1.615±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-(methylsulfonamido)-2-nitrobenzamide 在 iron(III) chloride 、 铁粉 、 氯化铵 、 对甲苯磺酸 作用下， 以 甲醇 、 水 为溶剂， 反应 4.0h， 生成 N-{2-[3-tert-butyl-2-methoxy-5-(2-oxo-1,2-dihydro-pyridin-3-yl)-phenyl]-4-oxo-3,4-dihydro-quinazolin-6-yl}-methanesulfonamide
  参考文献：
  名称：

  HETEROCYCLIC ANTIVIRAL COMPOUNDS

  摘要：

  具有公式I的化合物，其中R1、R2、R3b、R4a、R4b、R4c如本文所述定义，是丙型肝炎病毒NS5b聚合酶抑制剂。同时公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。

  公开号：

  US20100297073A1
• 作为产物：
  描述：

  5-氨基-2-硝基苯甲酸 在 吡啶 、 氯化亚砜 、 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 5-(methylsulfonamido)-2-nitrobenzamide
  参考文献：
  名称：

  A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues

  摘要：

  First structure-based activity prediction model of topologically diverse inhibitors of Palm I allosteric site of HCV NS5b polymerase enzyme is reported here. The model is a workflow of structure-based pharmacophore followed by guided docking. The pharmacophore was constructed using a novel procedure which includes PLIF (protein ligand interaction fingerprint), Hypogen, contact-based pharmacophore and shape constraints. The guided docking was tweaked using both a scoring function of high correlation with activity (ChemPLP) and essential pharmacophore features. Statistically, ROC analysis for the workflow, deploying the novel technique of virtual decoys, yielded AUC of 0.947. Experimentally, the model was used to screen Asinex GOLD database yielding a new hit with a different scaffold which was further confirmed by synthesis and biological evaluation. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.04.016

文献信息

• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Chin Elbert

  公开号：US20100297073A1

  公开（公告）日：2010-11-25

  Compounds having the formula I wherein wherein R 1 , R 2 , R 3b , R 4a , R 4b , R 4c and as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有公式I的化合物，其中R1、R2、R3b、R4a、R4b、R4c如本文所述定义，是丙型肝炎病毒NS5b聚合酶抑制剂。同时公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
• A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues
  作者：Amr H. Mahmoud、Dalal A. Abou El Ella、Mohamed A.H. Ismail、Khaled A.M. Abouzid

  DOI：10.1016/j.ejmech.2012.04.016

  日期：2012.11

  First structure-based activity prediction model of topologically diverse inhibitors of Palm I allosteric site of HCV NS5b polymerase enzyme is reported here. The model is a workflow of structure-based pharmacophore followed by guided docking. The pharmacophore was constructed using a novel procedure which includes PLIF (protein ligand interaction fingerprint), Hypogen, contact-based pharmacophore and shape constraints. The guided docking was tweaked using both a scoring function of high correlation with activity (ChemPLP) and essential pharmacophore features. Statistically, ROC analysis for the workflow, deploying the novel technique of virtual decoys, yielded AUC of 0.947. Experimentally, the model was used to screen Asinex GOLD database yielding a new hit with a different scaffold which was further confirmed by synthesis and biological evaluation. (C) 2012 Elsevier Masson SAS. All rights reserved.